Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

19:19
10/16/16
10/16
19:19
10/16/16
19:19

Celgene reports Phase 1b data on GED-0301 in Crohn's disease

Celgene announced that data from a phase 1b study evaluating the effects of investigational oral GED-0301, or mongersen, on both endoscopic response and clinical remission in patients with active Crohn's disease will be presented at the United European Gastroenterology Week. A total of 63 patients were enrolled in the study. The population was more diverse than prior GED-0301 studies and included patients with endoscopically confirmed mucosal damage at entry and those who had previous surgeries. Results showed that clinical improvement was seen by week 2, and clinical response and remission rates were highest in the 12-week treatment group at 67 and 48 percent respectively, at week 12. The mean CDAI reduction from baseline at week 12 in the 12-week treatment group was 133 points. Of the patients with evaluable endoscopies at week 12, 37 percent had an endoscopic response, with no meaningful difference across treatment groups. In addition, of those patients with greater endoscopic disease activity at baseline, 63 percent exhibited a reduction greater than or equal to 25 percent in SES-CD score and 31 percent had a reduction of greater than or equal to 50 percent. The rates of adverse events and serious adverse events were low and similar across treatment groups. There were no new safety signals for oral GED-0301 160 mg daily reported in this study.

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/16/16
RBCM
09/16/16
NO CHANGE
RBCM
Celgene shares can advance, says RBC Capital
RBC Capital analyst Michael Yee says that Celgene's stock "can grind higher" as investors eventually understand that the company's GED-0301 drug could potentially generate $1B in revenue. Yee says endoscopy data the company is expected to present next month on GED-0301 "isn't likely to be impressive." However, he thinks the data will "suggest that the drug is working," and he says that investor expectations are low, while the recent pullback in the shares has created an attractive entry point.
09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.

TODAY'S FREE FLY STORIES

WDC

Western Digital

$90.25

-0.78 (-0.86%)

11:25
06/23/17
06/23
11:25
06/23/17
11:25
Options
Western Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$30.88

0.6 (1.98%)

11:22
06/23/17
06/23
11:22
06/23/17
11:22
Periodicals
VW reducing workforce at core unit more quickly than planned, Reuters says »

Volkswagen is cutting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

11:18
06/23/17
06/23
11:18
06/23/17
11:18
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

$NSD

NASDAQ Market Internals

11:17
06/23/17
06/23
11:17
06/23/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/23/17
06/23
11:16
06/23/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$8.22

0.12 (1.48%)

11:10
06/23/17
06/23
11:10
06/23/17
11:10
Options
10K VALE Jan 10 calls trade at 40c on ISE »

10K VALE Jan 10 calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NURO

NeuroMetrix

$2.89

0.056 (1.98%)

11:08
06/23/17
06/23
11:08
06/23/17
11:08
Hot Stocks
NeuroMetrix provides update on Quell wearable pain relief clinical program »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$103.76

-0.08 (-0.08%)

11:08
06/23/17
06/23
11:08
06/23/17
11:08
Hot Stocks
As bar gets raised Deutsche Bank gets less bullish on Caterpillar »

Deutsche Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.87

0.44 (3.85%)

11:04
06/23/17
06/23
11:04
06/23/17
11:04
Earnings
Horizon Pharma now sees FY17 net sales $985M-$1.02B, consensus $990.53M »

In May, Horizon lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.87

0.44 (3.85%)

11:02
06/23/17
06/23
11:02
06/23/17
11:02
Hot Stocks
Horizon Pharma completes sale of European marketing rights for Procysbi »

Horizon Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.14

-0.09 (-0.36%)

11:00
06/23/17
06/23
11:00
06/23/17
11:00
Options
Large spread in UPS as shares deliver gains »

Large spread in UPS as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
06/23/17
06/23
11:00
06/23/17
11:00
General news
Breaking General news story  »

St. Louis Federal Reserve…

10:55
06/23/17
06/23
10:55
06/23/17
10:55
General news
Euro$ interest rate futures are marginally lower »

Euro$ interest rate…

NVO

Novo Nordisk

$44.13

0.46 (1.05%)

10:52
06/23/17
06/23
10:52
06/23/17
10:52
Hot Stocks
Novo Nordisk reports up to 13.8% weight loss in people receiving semaglutide »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.54

1.469 (1.35%)

10:45
06/23/17
06/23
10:45
06/23/17
10:45
Options
UPS call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

WMGI

Wright Medical

$26.99

0.11 (0.41%)

10:45
06/23/17
06/23
10:45
06/23/17
10:45
Conference/Events
Wright Medical has a conference call hosted by JPMorgan »

JPMorgan Analyst Hanover…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Jun

  • 28

    Jun

  • 03

    Jul

WDC

Western Digital

$90.25

-0.78 (-0.86%)

10:40
06/23/17
06/23
10:40
06/23/17
10:40
Technical Analysis
Technical View: Western Digital trades higher as Toshiba indicates open to talks »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$12.18

1.53 (14.37%)

10:31
06/23/17
06/23
10:31
06/23/17
10:31
Hot Stocks
Synchronoss confirms receipt of Siris Capital indication of interest »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$50.81

0.175 (0.35%)

10:31
06/23/17
06/23
10:31
06/23/17
10:31
Periodicals
Target starts removing all Hampton Creek products from stores, Bloomberg reports »

Target is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
06/23/17
06/23
10:30
06/23/17
10:30
General news
The 2.9% May U.S. new home sales rise »

The 2.9% May U.S. new…

YY

YY

$58.32

-0.66 (-1.12%)

10:28
06/23/17
06/23
10:28
06/23/17
10:28
Conference/Events
YY management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SYY

Sysco

$50.78

-1.9958 (-3.78%)

, USFD

US Foods

$26.33

-1.275 (-4.62%)

10:27
06/23/17
06/23
10:27
06/23/17
10:27
Hot Stocks
JPMorgan sees food distributors facing competition from Amazon »

Noting that Amazon's…

SYY

Sysco

$50.78

-1.9958 (-3.78%)

USFD

US Foods

$26.33

-1.275 (-4.62%)

PFGC

Performance Food Group

$26.00

-1.25 (-4.59%)

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ALGN

Align Technology

$149.69

0.27 (0.18%)

10:25
06/23/17
06/23
10:25
06/23/17
10:25
Conference/Events
Stifel medical technology analysts hold an analyst/industry conference call »

Research Team discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Jun

TM

Toyota

$105.10

-0.39 (-0.37%)

10:24
06/23/17
06/23
10:24
06/23/17
10:24
Conference/Events
Toyota management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AVEO

AVEO Oncology

$0.73

0.0281 (4.02%)

10:23
06/23/17
06/23
10:23
06/23/17
10:23
Recommendations
AVEO Oncology analyst commentary  »

Piper ups AVEO Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.